Endo International (NASDAQ:ENDP) PT Lowered to $1.00

Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) had its target price reduced by stock analysts at Barclays from $2.00 to $1.00 in a report released on Monday, The Fly reports. Barclays‘s price objective suggests a potential downside of 29.58% from the company’s current price.

ENDP has been the topic of several other research reports. StockNews.com assumed coverage on Endo International in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. BMO Capital Markets lowered their target price on shares of Endo International from $8.00 to $4.00 in a research note on Thursday, March 3rd. Piper Sandler cut shares of Endo International from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $3.00 to $1.00 in a research report on Friday. Zacks Investment Research lowered shares of Endo International from a “hold” rating to a “strong sell” rating and set a $2.50 price target on the stock. in a research report on Wednesday, February 9th. Finally, TheStreet downgraded shares of Endo International from a “c-” rating to a “d” rating in a report on Wednesday, February 2nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.07.

Endo International stock opened at $1.42 on Monday. The stock has a market capitalization of $331.81 million, a P/E ratio of -0.46 and a beta of 1.07. The company’s fifty day moving average price is $2.33 and its 200 day moving average price is $3.60. Endo International has a 1 year low of $1.28 and a 1 year high of $7.07.

Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) last announced its earnings results on Thursday, May 5th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.22. Endo International had a negative net margin of 24.82% and a negative return on equity of 82.00%. The business had revenue of $652.26 million for the quarter, compared to analyst estimates of $637.09 million. During the same quarter last year, the business earned $0.73 earnings per share. The company’s revenue for the quarter was down 9.1% compared to the same quarter last year. On average, sell-side analysts predict that Endo International will post 1.7 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of ENDP. Geode Capital Management LLC increased its holdings in shares of Endo International by 11.0% during the 4th quarter. Geode Capital Management LLC now owns 4,280,507 shares of the company’s stock worth $16,094,000 after buying an additional 425,177 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Endo International by 4.7% during the third quarter. Bank of New York Mellon Corp now owns 2,163,896 shares of the company’s stock worth $7,012,000 after acquiring an additional 97,708 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Endo International by 108.1% in the fourth quarter. Parametric Portfolio Associates LLC now owns 871,726 shares of the company’s stock valued at $3,278,000 after purchasing an additional 452,778 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Endo International by 12.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 470,795 shares of the company’s stock valued at $1,524,000 after purchasing an additional 52,535 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Endo International by 161.7% during the 1st quarter. New York State Common Retirement Fund now owns 426,139 shares of the company’s stock worth $984,000 after purchasing an additional 263,322 shares during the period. 80.39% of the stock is owned by institutional investors and hedge funds.

About Endo International (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Featured Articles